14h30-15h20  Salle des conférences, Bâtiment Espace Santé, site de Carreire, Université de Bordeaux

Le SIRIC BRIO invite Nicolas Leupin d’argenx à l’Université de Bordeaux afin de stimuler la réflexion et les échanges sur la recherche translationnelle en santé et les partenariats public-privé. MERCI de bien vouloir vous inscrire

With different outlooks and expertise, the academic world and the industry sector can either build fruitful synergies or remain ignorant of each other. What could be the ingredients for a successful partnership? Where are the complementarities?  From training MDs and PhDs in translational research, in order to help them adapt their research for an increased clinical impact, or create start-up biotech companies, to bringing specific ideas from the lab to the market, the health industry could have to lot to offer to students, staff and the academic institution itself. Nicolas Leupin from argenx will give an overview of possible pathways and set the scene for a discussion on translational health research in Bordeaux.

La présentation se fera en anglais, les questions pourront être en français.

MERCI de bien vouloir vous inscrire


Nicolas Leupin is a medical oncologist with a special interest in hematological oncology. He developed academic and clinical expertise, as well as experience in drug development. He worked for several years at Celgene, contributing to build the clinical development department in Europe, before becoming Chief Medical Officer argenx in February 2016. Argenx is a clinical-stage biotechnology company developing a pipeline of antibody-based therapies for the treatment of severe auto-immune diseases and cancer. Nicolas Leupin also holds an MBA with a focus on negotiation and conflict management, and is a lecturer at the University of Bern.